Business Wire

NY-REVIV

1.3.2024 13:36:33 CET | Business Wire | Press release

Share
Wellness Market Leaders Join Forces: The DRIPBaR Powered by REVIV

The DRIPBaR, recognized as the fastest-growing IV therapy franchise in the United States, has joined forces with REVIV, the global leader in IV therapy, marking a significant milestone for the industry. The partnership creates an unrivaled offering by bringing together the specialties of two industry heavyweights boasting over 200 locations across 6 continents, with plans to add thousands more locations in the coming years. The recent surge in demand for IV therapy presents enormous opportunities globally for the companies to redefine industry standards and spearhead the next era of IV therapy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240301173923/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Ben Crosbie, CEO of The DRIPBaR and Sarah Lomas, Founder and CEO of REVIV Global, announce their exciting partnership. (Photo: Business Wire)

With an extensive pipeline boasting over 450 franchisees in the United States, The DRIPBaR's decision to integrate REVIV's proprietary technology-backed proposition, REVIV X, validates their commitment to provide personalized and precision nutrition solutions for their customers. This partnership empowers The DRIPBaR to leverage REVIV's 10 years of intellectual property and life science expertise, utilizing objective data from blood tests and DNA analysis to tailor IV therapies to individual needs. Through REVIV X, The DRIPBaR is poised to revolutionize the wellness landscape in the United States, offering patient-focused solutions that optimize health outcomes that will solidify its position as a leader in innovation.

Ben Crosbie, CEO of The DRIPBaR, expressed excitement in the collaboration, affirming, "By selecting REVIV as our strategic partner, we are unlocking personalized and precision capabilities for a more advanced product offering and customer experience. I’m very confident that leveraging REVIV's cutting-edge technology and expertise will accelerate the growth of our franchisees and position them ahead of industry norms. The REVIV X proposition, coupled with its accredited IV Academy training course, sets a global benchmark for excellence in our field, empowering us to maintain industry leadership."

Sarah Lomas, Founder and CEO of REVIV Global, highlighted the transformative impact of the partnership, stating, "The DRIPBaR's alignment with REVIV underscores our joint dedication to innovation and safety in the IV therapy market. As industry leaders, we are reshaping the future of wellness by offering personalized and precision nutrition solutions that cater to evolving customer needs. We will continue to develop our SaaS products to power the industry globally. After many years and significant investment in research and product development, it’s exciting to see such early validation and adoption for REVIV X."

This strategic alliance between REVIV and The DRIPBaR marks a pivotal moment in the IV therapy industry and multi-modality sectors, advancing the delivery of safe, effective, and tailored wellness solutions to customers across the United States and beyond. As the IV therapy market continues its rapid expansion, with safety and compliance at the forefront, REVIV X emerges as the solution of choice for IV therapy operators, creating the opportunity for existing multi-modality businesses to access REVIV's innovative solutions and maintain their position at the forefront of wellness innovation and industry standards.

About REVIV Global

REVIV Global is at the forefront of advanced wellness solutions, devoted to enriching health and vitality through state-of-the-art IV therapy treatments. With a widespread international footprint and a relentless pursuit of innovation, REVIV is spearheading a revolution in the wellness sector. Its distinctive technological platform empowers IV therapy providers to deliver personalized and precision solutions with unparalleled safety and efficiency.

About The DRIPBaR

The DRIPBaR, a pioneering brand in the realm of wellness, is poised to redefine the landscape of health and vitality through advances in IV therapy. With cutting-edge science and a strong commitment to safety, The DRIPBaR offers a transformative approach to cellular health and personalized care. Focusing on ever-evolving treatments and medical advancements, The DRIPBaR embraces a new era of wellness where rejuvenation, vitality, and optimized health converge.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240301173923/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release

Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr

OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century

Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release

Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.

Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release

Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be

From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release

Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye